Encysive Pharmaceuticals Inc

Encysive Pharmaceuticals — JPMorgan Healthcare Conference 2006

27 slides from Encysive Pharmaceuticals's conference presentation, Jan 9, 2006

  1. Slide 1: JPMorgan Healthcare Conference January 9, 2006

    Slide 1: JPMorgan Healthcare Conference January 9, 2006

    JPMorgan Healthcare Conference January 9, 2006

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

  3. Slide 3: Introduction

    Slide 3: Introduction

    Introduction Encysive is engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds in the area of vascular biology.

  4. Slide 4: Encysive History

    Slide 4: Encysive History

    Encysive History TBC founded Argatroban licensed from MPC IPO IPI Acquisition 1989 1992 1993-94 1997 2000 2003 2006 GSK (SB) Argatroban ICOS-TBC JV Schering Plough Revotar Argatroban Launch Encysive Pharmaceuticals R&D Boutique Commercial Organization Thelin(tm) PDUFA

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    Investment Highlights Demonstrated ability to bring products through development Near-term FDA approval opportunity Management has successfully transformed Company into commercial organization Pipeline staged to fuel growth beyond Thelin(tm) into the next decade

  6. Slide 6: Pulmonary Arterial Hypertension: A Growing Market Opportunity

    Slide 6: Pulmonary Arterial Hypertension: A Growing Market Opportunity

    Pulmonary Arterial Hypertension A Growing Market Opportunity

  7. Slide 7: Pulmonary Arterial Hypertension

    Slide 7: Pulmonary Arterial Hypertension

    Pulmonary Arterial Hypertension Estimated 100,000 - 200,000 patients in NA and EU Efficient, concentrated market Relatively small sales force required (est. 50-60 reps in NA) Global premium pricing opportunity Market still in its infancy Physician awareness continues to grow Tracleer(r) (bosentan) h

  8. Slide 8: Projected PAH Diagnosis

    Slide 8: Projected PAH Diagnosis

    Projected PAH Diagnosis Source: Encysive, 2005

  9. Slide 9: Thelin: Conclusions on Clinical Benefit

    Slide 9: Thelin: Conclusions on Clinical Benefit

    Thelin(tm) __ Conclusions on Clinical Benefit Two pivotal trials completed STRIDE-2 under Special Protocol Assessment From FDA Thelin(tm) compares favorably to Tracleer(r) in STRIDE^2 31.4 meter 6MW improvement for Thelin(tm) vs 29.5 meter 6MW in for Tracleer(r) Interim, long-term data encouraging o

  10. Slide 10: ETRAs and 6MW: Change from Baseline

    Slide 10: ETRAs and 6MW: Change from Baseline

    24.9 22 49 58 0 37 22 38 49 0 23 29 70 Meters ETRAs and 6MW: Change from Baseline

  11. Slide 11: ETRAs and 6MW: Change from Baseline

    Slide 11: ETRAs and 6MW: Change from Baseline

    ETRAs and 6MW: Change from Baseline 24.9 22 49 58 0 37 22 38 49 0 23 29 70 Meters THELIN(tm) Tracleer(r) Ambrisentan STRIDE-2 STRIDE-1 Phase II Phase II Phase II ARIES II ARIES II BREATHE-1 Study 351 STRIDE-4 STRIDE-2 STRIDE-2

  12. Slide 12: Safety and Tolerability of Thelin

    Slide 12: Safety and Tolerability of Thelin

    Safety and Tolerability of Thelin(tm) Liver function test (LFT) elevations Class effect, seen with Tracleer(r) and ambrisentan 100 mg incidence looks reasonable (latest pivotal results: 3% for Thelin(tm), 11% for Tracleer(r)) at 18 weeks Interim data shows Thelin(tm) risk of 4% vs 14% with Tracleer(

  13. Slide 13: Warfarin Management: STRIDE-2

    Slide 13: Warfarin Management: STRIDE-2

    Warfarin Management: STRIDE-2 0 1 2 3 Placebo Thelin(tm) 50mg Tracleer(r) Mean Warfarin Dosing Changes Per Patient per 6 week interval Warfarin Dose at wk 18 (m +- SD) 3.7 +- 2.7 2.8 +- 1.2 2.1 +- 1.0 5.1 +- 2.9 End Dose: Thelin(tm) 100mg

  14. Slide 14: Encysive - Pipeline Positioned for Growth

    Slide 14: Encysive - Pipeline Positioned for Growth

    Encysive- Pipeline Positioned for Growth Near-term drivers Thelin(tm) in PAH Goal of share leader Market growth Medium-term drivers New indications for Thelin(tm) I.V. formulation opportunities

  15. Slide 15: Encysive - Pipeline Positioned for Growth

    Slide 15: Encysive - Pipeline Positioned for Growth

    Encysive- Pipeline Positioned For Growth Long-term drivers TBC3711 in chronic indications Pre-clinical candidates Potential in-license/Acquisition

  16. Slide 16: Pipeline Chart

    Slide 16: Pipeline Chart

    Pipeline Chart PROPRIETARY PRODUCTS Thelin(tm) Oral Thelin(tm) Oral PC1 Oral PC2 Oral PC3 Intravenous PAH Undisclosed ILD Thelin(tm) Oral Undisclosed Undisclosed TBC3711 Oral Thelin(tm) Intravenous TBC3711 Intravenous Undisclosed Undisclosed Undisclosed Resistant Hyper Undisclosed PARTNERED PRODUCTS

  17. Slide 17: Marketing in PAH

    Slide 17: Marketing in PAH

    Marketing in PAH

  18. Slide 18: Endothelial Dysfunction in PAH

    Slide 18: Endothelial Dysfunction in PAH

    Endothelial Dysfunction in PAH ET-1 is elevated (+) Vasoconstriction Cell proliferation and Hypertrophy NO and PGI2 are reduced (-) Vasodilation Anti-proliferation Anti-inflammation Anti-platelet effects ET-1 NO PGI2 Spieker LE et al. J Am Coll Cardiol. 2001;37:1493-1505. Luscher TF and Barton M. Ci

  19. Slide 19: Combination possibilities in PAH

    Slide 19: Combination possibilities in PAH

    Combination possibilities in PAH PDE-5 Inhibitors ETRAs Prostacyclins Revatio(tm) Tracleer(r) Flolan(r) Cialis(r)* Thelin(tm)* Remodulin(r) ambrisentan* Ventavis(r) * not FDA approved for PAH * not FDA approved for PAH

  20. Slide 20: The Key Question

    Slide 20: The Key Question

    The Key Question Why do we believe Thelin(tm) should win the share battle in PAH?

  21. Slide 21: Fast followers produce more revenue (McKinsey Quarterly)

    Slide 21: Fast followers produce more revenue (McKinsey Quarterly)

    "...the first drugs to treat an ailment often fail to create more value than their later-to-market competitors do. We found that fast followers- drugs marketed 2 to 5 years after their first-in-class predecessors-typically produce significantly more revenue." - -Booth and Zemmel, The McKinsey Quarte

  22. Slide 22: We Took a Big Pharma Approach

    Slide 22: We Took a Big Pharma Approach

    We Took a Big Pharma Approach Aimed at Regulatory Approvals and Marketing Success SPA with FDA Head-to-head competitor data 1,000+ patient database Broad patient inclusion criteria Well documented safety profile Highly experienced sales force hired (11 years average sales experience) Experienced pha

  23. Slide 23: Anticipated Catalysts for 2006

    Slide 23: Anticipated Catalysts for 2006

    Anticipated Catalysts for 2006 March PDUFA Date for Thelin(tm) Mid-Year EMEA Opinion for Thelin(tm) STRIDE-2X Data Expected at ATS in May • Long-term data: Thelin(tm) vs Tracleer(r) Results of Phase II dose-ranging trial with TBC-3711 in resistant hypertension possible by year end

  24. Slide 24: 2005 Financial Guidance

    Slide 24: 2005 Financial Guidance

    2005 Financial Guidance $ millions Net loss FY2005 ($75.0) - ($84.0) Cash & investments at Year End $110 - $115 Actual Cash & investments at Sept. 30, 2005 $146.8

  25. Slide 25: Thelin represents a rare opportunity

    Slide 25: Thelin represents a rare opportunity

    Thelin(tm) represents one of those truly rare opportunities - a product with the potential to transform an entire company. Management is focused on realizing the full potential of Thelin(tm) while positioning the pipeline for sustainable growth for the long term.

  26. Slide 26: Forward Looking Statements

    Slide 26: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

  27. Slide 27: JPMorgan Healthcare Conference January 9, 2006

    Slide 27: JPMorgan Healthcare Conference January 9, 2006

    JPMorgan Healthcare Conference January 9, 2006

Source: SEC EDGAR · 8-K filed Jan 9, 2006

More decks from Encysive Pharmaceuticals Inc